Literature DB >> 26330296

Myeloid-derived suppressor cells in B cell malignancies.

Yaghoub Yazdani1, Mousa Mohammadnia-Afrouzi2, Mehdi Yousefi3,4, Enayat Anvari5, Ghasem Ghalamfarsa6, Hadi Hasannia7, Sanam Sadreddini3, Farhad Jadidi-Niaragh8.   

Abstract

Tumor cells use several mechanisms such as soluble immune modulators or suppressive immune cells to evade from anti-tumor responses. Immunomodulatory cytokines, such as transforming growth factor-β, interleukin (IL)-10, and IL-35, soluble factors, such as adenosine, immunosuppressive cells, such as regulatory T cells, NKT cells and myeloid-derived suppressor cells (MDSCs), are the main orchestra leaders involved in immune suppression in cancer by which tumor cells can freely expand without immune cell-mediated interference. Among them, MDSCs have attracted much attention as they represent a heterogenous population derived from myeloid progenitors that are expanded in tumor condition and can also shift toward other myeloid cells, such as macrophages and dendritic cells, after tumor clearing. MDSCs exert their immunosuppressive effects through various immune and non-immune mechanisms which make them as potent tumor-promoting cells. Although, there are several studies regarding the immunobiology of MDSCs in different solid tumors, little is known about the precise characteristics of these cells in hematological malignancies, particularly B cell malignancies. In this review, we tried to clarify the precise role of MDSCs in B cell-derived malignancies.

Entities:  

Keywords:  B cell malignancies; Immune suppression; Leukemia; Lymphoma; Multiple myeloma; Myeloid-derived suppressor cells

Mesh:

Year:  2015        PMID: 26330296     DOI: 10.1007/s13277-015-4004-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  143 in total

1.  Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.

Authors:  X G Zhang; R Bataille; M Jourdan; S Saeland; J Banchereau; P Mannoni; B Klein
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 2.  The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis.

Authors:  Andrew Martins; Jiahuai Han; Sung O Kim
Journal:  IUBMB Life       Date:  2010-08       Impact factor: 3.885

3.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

Authors:  Svetlana Karakhanova; Julia Link; Moritz Heinrich; Ivan Shevchenko; Yuhui Yang; Matthias Hassenpflug; Henriette Bunge; Katharina von Ahn; Ramona Brecht; Andreas Mathes; Caroline Maier; Viktor Umansky; Jens Werner; Alexandr V Bazhin
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

4.  Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.

Authors:  David J Betting; Sara A Hurvitz; Kristopher K Steward; Reiko E Yamada; Kamran Kafi; Nico van Rooijen; John M Timmerman
Journal:  J Immunother       Date:  2012-09       Impact factor: 4.456

Review 5.  Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Authors:  Ngozi R Monu; Alan B Frey
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

Review 6.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

7.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

9.  Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin.

Authors:  Veronica Munera; Petar J Popovic; Jodie Bryk; John Pribis; David Caba; Benjamin M Matta; Mazen Zenati; Juan B Ochoa
Journal:  Ann Surg       Date:  2010-01       Impact factor: 12.969

Review 10.  Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.

Authors:  Hiroshi Katoh; Masahiko Watanabe
Journal:  Mediators Inflamm       Date:  2015-05-19       Impact factor: 4.711

View more
  16 in total

Review 1.  A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.

Authors:  Christopher Shipp; Lisa Speigl; Nicole Janssen; Alexander Martens; Graham Pawelec
Journal:  Cell Mol Life Sci       Date:  2016-05-28       Impact factor: 9.261

2.  Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.

Authors:  Asal Barshidi; Vahid Karpisheh; Fatemeh Karimian Noukabadi; Fariba Karoon Kiani; Mohammad Mohammadi; Negin Afsharimanesh; Farbod Ebrahimi; Seyed Hossein Kiaie; Jamshid Gholizadeh Navashenaq; Mohammad Hojjat-Farsangi; Naime Majidi Zolbanin; Ata Mahmoodpoor; Hadi Hassannia; Sanam Nami; Pooya Jalali; Reza Jafari; Farhad Jadidi-Niaragh
Journal:  Pharm Res       Date:  2022-06-17       Impact factor: 4.580

Review 3.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

4.  Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.

Authors:  Farhad Jadidi-Niaragh; Fatemeh Atyabi; Ali Rastegari; Esmail Mollarazi; Melika Kiani; Alireza Razavi; Mehdi Yousefi; Nasim Kheshtchin; Hadi Hassannia; Jamshid Hadjati; Fazel Shokri
Journal:  Tumour Biol       Date:  2016-01-05

Review 5.  Emerging targets for radioprotection and radiosensitization in radiotherapy.

Authors:  Sumit Kumar; Rajnish Kumar Singh; Ramovatar Meena
Journal:  Tumour Biol       Date:  2016-06-19

6.  Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

Authors:  David F Stroncek; Jiaqiang Ren; Daniel W Lee; Minh Tran; Sue Ellen Frodigh; Marianna Sabatino; Hanh Khuu; Melinda S Merchant; Crystal L Mackall
Journal:  Cytotherapy       Date:  2016-05-17       Impact factor: 5.414

7.  Targeting of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model.

Authors:  Fatemeh Hosseini; Hadi Hassannia; Ahmad Mahdian-Shakib; Farhad Jadidi-Niaragh; Seyed Ehsan Enderami; Mohammadjavad Fattahi; Ali Anissian; Abbas Mirshafiey; Parviz Kokhaei
Journal:  Cancer Med       Date:  2017-02-17       Impact factor: 4.452

8.  Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.

Authors:  David F Stroncek; Daniel W Lee; Jiaqiang Ren; Marianna Sabatino; Steven Highfill; Hanh Khuu; Nirali N Shah; Rosandra N Kaplan; Terry J Fry; Crystal L Mackall
Journal:  J Transl Med       Date:  2017-03-16       Impact factor: 5.531

Review 9.  Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

Authors:  Adam J Lamble; Evan F Lind
Journal:  Front Oncol       Date:  2018-06-13       Impact factor: 6.244

Review 10.  Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses.

Authors:  Bilgenaz Özkan; Heejin Lim; Sung-Gyoo Park
Journal:  Int J Mol Sci       Date:  2018-05-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.